Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
Zijun Y. Xu‐Monette(Duke University), Ken H. Young(Duke Medical Center), Karen Dybkær(Aalborg University Hospital), Govind Bhagat(Columbia University Irving Medical Center), Maurilio Ponzoni(San Raffaele University of Rome), Yi Miao(Jiangsu Academy of Agricultural Sciences), Bing Xu(First Affiliated Hospital of Xiamen University), Ilan R. Kirsch(Adaptive Biotechnologies (United States)), Eric D. Hsi(Mayo Clinic), J. Han van Krieken(Radboud University Nijmegen), Alexandar Tzankov(University of Basel), Carlo Visco(University of Verona), Hua You(Soochow University), Thomas M. Snyder(Adaptive Biotechnologies (United States)), Wayne Tam(Cornell University), Min Xiao(Tongji Hospital), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Ganiraju C. Manyam(The University of Texas MD Anderson Cancer Center), Beryl Crossley(Adaptive Biotechnologies (United States)), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Jooryung Huh(Asan Medical Center), Yong Li(Baylor College of Medicine), Hongwei Zhang(Georgia Southern University), Jianyong Li(Jiangsu Province Hospital), Xiaohong Tan(Beijing Proteome Research Center), Yi Xia(The University of Texas MD Anderson Cancer Center), Robert D. Bremel(ioGenetics (United States)), L. Jeffrey Medeiros(Delaware Division of Libraries), Jane N. Winter(Northwestern University), Michael Møller(Hospital South West Jutland)
Cited by 28
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
|Cell|2016|2.4k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k